Observational studyBreast cancer (Tokyo, Japan)2024

Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study.

Tetsuhiro Yoshinami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.